triamcinolone acetonide topical / Generic mfg. - LARVOL DELTA

Blaschko-Linear Lupus Erythematosus in a Pediatric Patient. (PubMed, HCA Healthc J Med) - "The patient was treated with intralesional triamcinolone, topical pimecrolimus, and systemic hydroxychloroquine with an emphasis on strict photo-protection. Despite these therapies the patient's disease persisted."

Journal • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Pediatrics

Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (IMW 2023) - P1, P2 | "Management of dermatologic AEs included a heavy moisturizer for general dryness; ammonium lactate 12% lotion twice daily (BID) for hand and foot peeling; loratadine 10 mg oral tablet daily for 3–5 days post dose and triamcinolone 0.1% cream BID for pruritus, injection-site reaction, and rash; and nail hardeners, topical vitamin E oil, and triamcinolone 0.025% ointment for nail thinning and peeling. Talquetamab is an effective therapy for patients with RRMM. Skin and nail AEs are common but are primarily low grade with no discontinuations. Appropriate management, education, and supportive care ensure that patients can stay on treatment to receive optimal benefit from talquetamab."

Clinical • Dermatology • Hematological Malignancies • Multiple Myeloma • Oncology • Pruritus

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (IMW 2022) - " Management of palmar/plantar desquamation, nail disorders, and injection site reaction is ammonium lactate 12% cream, triamcinolone 0.1% cream, with plain Vaseline and Vanicream applied twice daily. Dermatologic and oral AEs have unknown etiologies and are currently under investigation. These AEs are low grade, rarely require dose holds or modifications, and have been manageable with early and consistent supportive care. One patient to date has discontinued treatment due to an oral or dermatologic side effect."

Clinical • Dermatology • Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • Oncology • Xerostomia

Recurrent Bullous Pemphigoid: A Case Report. (PubMed, Cureus) - "The article enlightens the occurrence of bullous pemphigoid in a 68-year-old male who complained of a burning sensation in his oral cavity. The diagnosis was exclusively based on history and clinical examination without any intervention by histopathological or immunofluorescent tests."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment (clinicaltrials.gov) - P2 | N=56 | Completed | Sponsor: Dar Al Uloom University | Phase classification: P2/3 ➔ P2 | Recruiting ➔ Completed

Phase classification • Trial completion • Dermatology • Dermatopathology • Lichen Planus

Subconjunctival triamcinolone acetate versus topical steroid for control of inflammation after phacoemulsification surgery - A randomized control trial. (PubMed, Indian J Ophthalmol) - "Subconjunctival triamcinolone is noninferior to topical steroids in controlling post-phacoemulsification intraocular inflammation."

Journal • Anesthesia • Cataract • Hematological Disorders • Inflammation • Macular Edema • Ophthalmology

Topical Treatment for Atopic Dermatitis (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jul 2027 ➔ Nov 2027 | Trial primary completion date: Jul 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy of Topical Cannabidiol for Eczema (clinicaltrials.gov) - P2 | N=60 | Enrolling by invitation | Sponsor: Khon Kaen University | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: May 2026 ➔ Aug 2027 | Active, not recruiting ➔ Enrolling by invitation

Enrollment open • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis • Pruritus

Hyaluronidase attenuates radiation-induced skin fibrosis through extracellular matrix remodeling and suppression of inflammatory-profibrotic signaling. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "After a 28-day fibrosis-development period, irradiated mice received saline, topical 0.1% triamcinolone acetonide, or hyaluronidase every 2 days for 2 weeks and non-irradiated mice served as normal controls...Hyaluronidase also reduced TNF-α, IL-6, MCP-1, and IL-1β levels and downregulated Tgfb1, Acta2, Col1a1, Il4, Il13, and Il31 expression. Local hyaluronidase treatment attenuated functional, histologic, inflammatory, and molecular features of radiation-induced skin fibrosis."

Journal • Fibrosis • Immunology • Inflammation • ACTA2 • COL1A1 • IL13 • IL1B • IL4 • IL6 • TGFB1 • TNFA

Comparative Efficacy and Safety of Adjunctive 0.015% Triamcinolone Acetonide Topical Spray With Lokivetmab Versus Lokivetmab Monotherapy as 'Reactive Therapy' for Canine Atopic Dermatitis: A Randomised, Single-Blinded, Controlled Preliminary Trial. (PubMed, Vet Dermatol) - "Topical application of TCA spray may be a useful and safe adjunctive therapy for systemic lokivetmab to alleviate pruritus and clinical lesions in the initial management of canine AD patients."

Journal • Monotherapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Management of Mucocutaneous and Joint Involvement of Behçet's Syndrome: A Systematic Literature Review Informing the 2025 Update of the EULAR Recommendations (EULAR 2026) - "Infliximab and interferon-alpha demonstrated comparable efficacy in two RCTs, one of which included a third comparator, cyclosporine-A...Topical tacrolimus was superior to placebo and diode laser treatment was superior to topical triamcinolone for oral ulcers...BD mouthwash containing a combination of 500 µg betamethasone soluble tablets, 100 mg doxycycline, and 1 mL nystatin oral suspension was significantly more beneficial for oral ulcers than both betamethasone mouthwash alone and no mouthwash. The observational non-comparative studies with ustekinumab, secukinumab, adalimumab, and roflumilast did not allow us to draw definite conclusions regarding their efficacy due to the absence of comparator groups. Conclusions Apremilast demonstrated efficacy in a phase 3 RCT for oral ulcers in patients refractory to conventional agents. The mean number of oral ulcers was similar between infliximab and adalimumab, infliximab and interferon- alpha, and infliximab and..."

Review • Rare Diseases • IFNA1

Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial. (PubMed, Front Med (Lausanne)) - "Meanwhile, the foundational therapies include desonide cream for mild AD and triamcinolone acetonide cream for moderate AD, both of which will be applied twice daily for 2 weeks. Findings in this study are expected to provide evidence for the incorporation of traditional Chinese herbal bath solutions into the comprehensive management of AD. https://www.chictr.org.cn/, Identifier ITMCTR2025001206."

Clinical • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

A randomized, phase II, double-blinded study of the efficacy of oleogel-S10 (AP101) gel for the treatment of grade 2/3 radiation dermatitis in breast cancer patients. (ASCO 2026) - P2 | "Patients were randomized 1:1 to Oleogel-S10 or placebo and instructed to apply standard-of-care triamcinolone 0.1% cream daily with study gel nightly for three weeks. Although Oleogel-S10 did not improve the primary endpoint of wound surface area as calculated by a novel 3D imaging tool compared with standard-of-care triamcinolone, treatment was associated with a trend toward improvement in skin pain and hyperpigmentation. These findings may represent early signals of therapeutic activity in ARD, particularly for patient-centered outcomes. Interpretation is limited by early study closure related to COVID-19–associated recruitment challenges and small sample size."

Clinical • P2 data • Breast Cancer • Dermatitis • Dermatology • Immunology • Infectious Disease • Oncology • Pruritus • Skin Cancer • Solid Tumor

Palatal Wound Healing After Free Gingival Graft Surgery (clinicaltrials.gov) - P=N/A | N=55 | Recruiting | Sponsor: Kahramanmaras Sutcu Imam University | N=34 ➔ 55

Enrollment change • HEOR

COMBINED INTRALESIONAL AND TOPICAL CORTICOSTEROIDS FOR IDIOPATHIC GRANULOMATOUS MASTITIS: A PROSPECTIVE PILOT CASE SERIES (BMC-BBCS 2026) - "Lesions ≤5 cm on ultrasound were treated with intralesional methylprednisolone (40 mg) at two-week intervals, combined with continuous topical triamcinolone acetonide 0.1% ointment... This combined local corticosteroid regimen demonstrated rapid clinical response, favorable safety, and the potential to control recurrences without systemic therapy. These findings support a steroid-sparing strategy in IGM management and provide preliminary evidence for a minimally invasive, outpatient-based approach. Larger controlled studies are warranted to validate these results."

Clinical • Inflammation

When Antidiabetic Therapy Affects the Skin – case report and literature review. (EADV-Sp 2026) - "Initial dermatological management included systemic antihistamines and topical triamcinolone combined with tetracycline spray...The patient was maintained on metformin monotherapy...This drug class includes canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin [3]...Conclusions In the present case, blistering lesions developed after more than one year of empagliflozin therapy and showed partial remission following drug substitution and complete resolution after discontinuation of SGLT2 inhibitor treatment , suggesting a possible association with a non-autoimmune bullous reaction. This observation highlights the importance of considering SGLT2 inhibitors (flozins) in the in the differential diagnosis of bullous or blistering skin eruptions in patients with type 2 diabetes mellitus."

Case report • Clinical • Review • Bullous Pemphigoid • Cardiovascular • Dermatopathology • Diabetes • Hypotension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Pruritus • Psoriasis • Type 2 Diabetes Mellitus

Persistent mycoplasma serologies in a patient with recurrent MIRM/EM-spectrum (SID 2026) - "She was formulated to have MIRM and started on azithromycin and topical triamcinolone 0.1% and mupirocin. She was re-hospitalized twice in the subsequent 3 months for EM-like targetoid papules: first, for periorbital involvement, eye swelling, and conjunctivitis, treated with prednisone, valacyclovir, dapsone, and azithromycin; and second, while tapering prednisone, with truncal involvement...Our case demonstrates that Mycoplasma serologies may be elevated during flares of MIRM/EM spectrum diseases in the absence of M. pneumoniae or M. genitalium NAT positivity or Mycoplasma 16S RNA on biopsy. These findings raise the possibility that clonally-expanded Mycoplasma-specific B cells, rather than infection itself, may lead to antibody-mediated direct injury (i.e. through molecular mimicry) or indirect injury, particularly in recurrent cases."

Clinical • Asthma • Conjunctivitis • Dermatitis • Immunology • Infectious Disease • Mucositis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pneumonia • Respiratory Diseases

Drug-induced morphea following complement c5 inhibition with zilucoplan: A case report (SID 2026) - "Cutaneous lesions stabilized with topical triamcinolone 0.1%, clobetasol 0.05%, and systemic methotrexate (10 mg weekly); however, complete clinical remission was not achieved. This case suggests a potential association between complement inhibition and sclerotic cutaneous immune dysregulation, underscoring the importance of dermatologic monitoring in patients receiving novel complement-targeted therapies."

Case report • Clinical • CNS Disorders • Immunology • Myasthenia Gravis

Paradoxical Vitiligo Outcomes with Dupilumab Use: A Systematic Review (EADV-Sp 2026) - "Various treatments were introduced, including topical corticosteroids, tacrolimus 0.1% ointment, triamcinolone acetonide 0.1% ointment, and narrowband UVB (NBUVB) phototherapy [8-14]. Given the limited number of reported cases and the absence of controlled studies, no definitive conclusions can be made regarding the role of dupilumab in vitiligo onset or treatment. Further research including larger studies and better investigations is needed to clarify its impact on melanocyte function and identify potential risk factors for pigmentary changes in patients receiving dupilumab."

Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Vitiligo

First Molecularly Confirmed Outbreak of Bovine Pythiosis Caused by Pythium insidiosum in the Amazon Biome. (PubMed, Pathogens) - "Therapeutic interventions were implemented as part of routine field management, including intramuscular triamcinolone combined with topical copper sulfate; this regimen was associated with clinical improvement in a substantial proportion of affected animals, though treatment efficacy was not formally evaluated. The outbreak occurred in flood-prone pastures during the rainy season, highlighting the role of aquatic environments in pathogen transmission. These findings expand the current understanding of bovine pythiosis in tropical ecosystems and underscore the importance of molecular diagnostics, outbreak surveillance, and a One Health approach for the identification and management of water-associated pathogens in livestock."

Journal • Infectious Disease

A multicenter, randomized, controlled study on the treatment of erosive oral lichen planus with methylene blue-mediated photodynamic therapy combined with local glucocorticoids (ChiCTR) - P=N/A | N=182 | Sponsor: The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; The Ninth People's Hospital Affiliated to Shanghai Jiao To

New trial • Dermatology • Dermatopathology • Lichen Planus

Health Insurance Coverage of Topical Medications in Vitiligo and Atopic Dermatitis (AAD 2026) - "Given limited coverage of topical tacrolimus and narrowband UVB phototherapy described prior to ruxolitinib approval, we performed cross-sectional analysis of topical ruxolitinib coverage versus other first-line agents in vitiligo with atopic dermatitis (AD) for comparison...Of 80 commercial insurance organizations and seven Medicaid programs, 57/87 (65.5%) covered ruxolitinib 1.5% cream, 82/87 (94.3%) covered tacrolimus 0.03% ointment, and 87/87 (100%) covered triamcinolone 0.1% ointment for vitiligo (p<0.001), compared to 57/87 (65.5%), 87/87 (100%), and 87/87 (100%), respectively, for AD (p<0.001), a statistically significant difference in coverage between drug types for both diseases...For plans with coverage, the median number of stipulations for coverage for vitiligo was three for ruxolitinib, two for tacrolimus, and none for triamcinolone (p<0.0001, Kruskal-Wallis). Though ruxolitinib is the only FDA-approved therapeutic for vitiligo, it remains less..."

Reimbursement • US reimbursement • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Vitiligo

Eosinophilic Annular Erythema with Marked Hypereosinophilia in an Adult: A Case Report of Successful Dupilumab Therapy (AAD 2026) - "While therapies such as antimalarials and dapsone have shown variable success, dupilumab has recently demonstrated promise in a small number of case reports for achieving sustained remission...Treatment was initiated with topical triamcinolone, oral antihistamines, and off-label dupilumab...It highlights the need to distinguish EAE from Wells syndrome or hypereosinophilic syndrome in such presentations. Furthermore, the patient’s response to dupilumab supports the growing body of literature indicating that IL-4/IL-13 inhibition may be an effective therapeutic strategy in refractory eosinophilic annular erythema."

Case report • Clinical • Dermatology • Eosinophilia • Hematological Malignancies • Hypereosinophilic Syndrome • Immunology • Infectious Disease • Nephrology • Pruritus • Renal Disease • Vasculitis • IL13 • IL4

From Catheterization to Cutaneous Reaction: A Case of Iododerma (AAD 2026) - "Punch biopsy was performed, and the patient was started on oral valacyclovir prophylactically and topical triamcinolone cream. This case emphasizes the need to consider iododerma in patients with new bullous eruptions following iodinated contrast exposure. Early recognition can prevent unnecessary antiviral or immunosuppressive therapy."

Clinical • Cardiovascular • Contact Dermatitis • Dermatitis • Immunology • Infectious Disease • Mood Disorders • Myocardial Infarction

Sweet Syndrome Masquerading as Sporotrichosis: A Novel Association with Adrenal Adenoma (AAD 2026) - "She received repeated courses of itraconazole, cephalexin, and naproxen from infectious disease specialists, yet lesions recurred independent of gardening exposures...Lesions temporarily resolved with triamcinolone 0.1% ointment...Given the absence of other causes, we propose this functional adrenal adenoma, with potential for hormone dysregulation and neutrophilic infiltration, as the most likely driver of her recalcitrant SS. To our knowledge, this represents the first reported case of sweet syndrome secondary to an adrenal adenoma."

Dermatitis • Dermatology • Discoid Lupus Erythematosus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Rare Diseases • Sarcoidosis • Vasculitis